Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Kesavan, Suresh K ^a   Bhat, Shweta ^a   Golegaonkar, Sandeep B ^a   Jagadeeshaprasad, Mashanipalya G ^a   Deshmukh, Arati B ^a   Patil, Harshal S ^a   Bhosale, Santosh D ^a   Shaikh, Mahemud L ^b   Thulasiram, Hirekodathakallu V ^a   Boppana, Ramanamurthy ^b   Kulkarni, Mahesh J ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; CREATININE; HYDRALAZINE; PROTEOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLYCOSYLATION; HUMAN; KIDNEY; MALE; METABOLISM; METHODOLOGY; MOUSE; PROTEOMICS; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD UREA NITROGEN; CHOLESTEROL; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDRALAZINE; KIDNEY; MALE; MICE; NADPH OXIDASE; PROTEOME; PROTEOMICS; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIGLYCERIDES;

EID: 84903679999     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02941     Document Type: Article

References (47)

1. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
2. Piperi, C., Adamopoulos, C., Dalagiorgou, G., Diamanti-Kandarakis, E. & Papavassiliou, A. G. Crosstalk between Advanced Glycation and Endoplasmic Reticulum Stress: Emerging Therapeutic Targeting for Metabolic Diseases. J Clin Endocrinol Metab. 97, 2231-2242.
3. Brownlee, M. D. M. Advaced protein glycosylation in diabetes and aging. Annu Rev Med. 46, 223-234 (1995).
4. Kulkarni, M. J., and Korwar, A. M., Mary, S., Bhonsle, H. S. & Giri, A. P. Glycated proteome: From reaction to intervention. Proteomics Clin Appl. 7, 155-170 (2013).
5. Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P. & Cerami, A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232, 1629-1632 (1986).
6. Miyata, T. et al. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett. 445, 202-206 (1999).
7. Forbes, J. M. et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44, 108-114 (2001).
8. Beisswenger, P. & Ruggiero-Lopez, D. Metformin inhibition of glycation processes. Diabetes Metab. 29, 6S95-6S103 (2003).
9. Huby, R. & Harding, J. J. Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione. Exp Eye Res. 47, 53-59 (1988).
10. van Boekel, M. A. M., van den Bergh, P. J. P. C. & Hoenders, H. J. Glycation of human serum albumin: inhibition by Diclofenac. Biochim Biophys Acta 1120, 201-204 (1992).
11. Szwergold, B. S., Howell, S. & Beisswenger, P. J. Human Fructosamine-3-Kinase. Diabetes 50, 2139-2147 (2001).
12. Szwergold, B. S., Howell, S. K. & Beisswenger, P. J. Transglycation - A Potential New Mechanism for Deglycation of Schiff's Bases. Ann N Y Acad Sci. 1043, 845-864 (2005).
13. Golegaonkar, S. B., and Bhonsle, H. S., Boppana, R. & Kulkarni, M. J. Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ ionization mass spectrometry-based insulin glycation assay. Eur J Mass Spectrom (Chichester, Eng). 16, 221-6 (2010).
14. Yanagisawa, K. et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 47, 1348-53 (1998).
15. Silva, J. C., and Gorenstein, M. V., Li, G.-Z., Vissers, J. P. C. & Geromanos, S. J. Absolute Quantification of Proteins by LCMSE: A Virtue of Parallel ms Acquisition. Mol Cell Proteomics 5, 144-156 (2006).
16. Xie, H., Gilar, M. & Gebler, J. C. Characterization of Protein Impurities and Site-Specific Modifications Using Peptide Mapping with Liquid Chromatography and Data Independent Acquisition Mass Spectrometry. Anal Chem. 81, 5699-5708 (2009).
17. Blackburn, K. & Goshe, M. B. Challenges and strategies for targeted phosphorylation site identification and quantification using mass spectrometry analysis. Brief Funct Genomic Proteomic. 8, 90-103 (2009).
18. Bhonsle, H. S. et al. Low Plasma Albumin Levels Are Associated with Increased Plasma Protein Glycation and HbA1c in Diabetes. J Proteome Res. 11, 1391-1396 (2012).
19. Bansode, S. B. et al. Proteomic Analysis of Protease Resistant Proteins in the Diabetic Rat Kidney. Mol Cell Proteomics 12, 228-236 (2013).
20. Zhang, M. X. W. & Deng, Y. A New Strategy for Early Diagnosis of Type 2 Diabetes Mellitus by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides. Diabetes E-pub (2013).
21. Makita, Z. et al. Advanced Glycosylation End Products in Patients with Diabetic Nephropathy. N Engl J Med. 325, 836-842 (1991).
22. Yan, S.F., Ramasamy, R., Naka, Y. & Schmidt, A.M. Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond. Circ Res. 93, 1159-1169 (2003).
23. Peyroux, J. & Sternberg, M. Advanced glycation endproducts (AGEs): pharmacological inhibition in  diabetes. Pathol Biol (Paris). 54, 405-419 (2006).
24. Khalifah, R. G., Chen, Y. & Wassenberg, J. J. Post-Amadori AGE Inhibition as a Therapeutic Target for Diabetic Complications: A Rational Approach to Second-Generation Amadorin Design. Ann N Y Acad Sci. 1043, 793-806 (2005).
25. Khalifah, R. G., Baynes, J. W. & Hudson, B. G. Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions. Biochem Biophys Res Commun. 257, 251-258 (1999).
26. Ruggiero-Lopez, D. et al. Reaction of metformin with dicarbonyl compounds. possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol. 58, 1765-1773 (1999).
27. Asif, M. et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proceed Natl Acad Sci. 97, 2809-2813 (2000).
28. Costantino, L., Rastelli, G., Vianello, P., Cignarella, G. & Barlocco, D. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches. Med Res Rev. 19, 3-23 (1999).
29. Shinohara, M. et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest. 101, 1142-1147 (1998).
30. Goova, M. T. et al. Blockade of Receptor for Advanced Glycation End-Products Restores Effective Wound Healing in Diabetic Mice. Am J Pathol. 159, 513-525 (2001).
31. Shakkottai, V. G., Sudha, R. & Balaram, P. Gramicidin S: a peptide model for protein glycation and reversal of glycation using nucleophilic amines. J Pept Res. 60, 112-120 (2002).
32. Babizhayev, M. A., Micans, P., Guiotto, A. & Kasus-Jacobi, A. N-Acetylcarnosine Lubricant Eyedrops Possess All-In-One Universal Antioxidant Protective Effects of L-Carnosine in Aqueous and Lipid Membrane Environments, Aldehyde Scavenging, and Transglycation Activities Inherent to Cataracts: A Clinical Study of the New Vision-Saving Drug N-Acetylcarnosine Eyedrop Therapy in a Database Population of Over 50,500 Patients. Am J Ther. 16, 517-533, 10.1097/MJT.0b013e318195e327 (2009).
33. Brown, B. E., and Mahroof, F. M., Cook, N. L., Reyk, D. M. & Davies, M. J. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 49, 775-783 (2006).
34. Rodrigues, B., Goyal, R. K. & McNeill, J. H. Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function. J Pharmacol Exp Ther. 237, 292-299 (1986).
35. Burcham, P. C., and Kaminskas, L. M., Fontaine, F. R., Petersen, D. R. & Pyke, S. M. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 181-182, 229-236 (2002).
36. Kaminskas, L. M., Pyke, S. M. & Burcham, P. C. Strong Protein Adduct Trapping Accompanies Abolition of Acrolein-Mediated Hepatotoxicity by Hydralazine in Mice. J Pharmacol Exp Ther. 310, 1003-1010 (2004).
37. Galvani, S. et al. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med. 45, 1457-67 (2008).
38. Nickerson, M. & Carter, S. A. Protection against acute trauma and traumatic shock by vasodilators. Can J Biochem Physiol. 37, 1161-1171 (1959).
39. Wang, J. et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 117, 3393-3402 (2007).
40. Lapolla, A. et al. Advanced glycation end products: a highly complex set of biologically relevant compounds detected bymass spectrometry. J Mass Spectrom. 36, 370-378 (2001).
41. Batirel, S., Yarat, A. & Emekli, N. Effects of short-term streptozotocin-induced diabetes and vitamin C on platelet non-enzymatic glycation. Pathophysiol Haemost Thromb. 37, 72-6.
42. Chen, J., and Kuhlencordt, P. J., Astern, J., Gyurko, R. & Huang, P. L. Hypertension Does Not Account for the Accelerated Atherosclerosis and Development of Aneurysms in Male Apolipoprotein E/Endothelial Nitric Oxide Synthase Double Knockout Mice. Circulation 104, 2391-2394 (2001).
43. Youssef, S. et al. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. 55, 907-916 (1999).
44. Salek, R. M. et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 29, 99-108 (2007).
45. Chen, L., Wei, Y., Wang, X. & He, R. Ribosylation Rapidly Induces alpha-Synucleinto Form Highly Cytotoxic Molten Globules of Advanced Glycation End Products. PLoS ONE 5, e9052 (2010).
46. Shaban, M. A. E., Ali, R. S. & El-Badry, S. M. The synthesis of 3-(alditol-1-yl)-1,2,4-triazolo[3,4-a]phthalazines. Carbohydr Res. 95, 51-60 (1981).
47. Want, E. J. et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protocols 5, 1005-1018 (2010).